德国埃尔朗根-纽伦堡大学Ferdinand Knieling课题组在研究中取得进展。他们利用多光谱光声层析成像术（MSOT）检测胶原，从而作为杜氏肌营养不良的影像学生物标志物。该研究2019年12月2日在线发表于《自然—医学》。

研究人员报道了MSOT的一种应用，其中在680-1100 nm的近红外和扩展近红外范围内进行照明可以实现胶原蛋白含量的可视化和定量。研究人员首先在大动物杜兴氏肌营养不良模型（猪）的纵向研究中证明了这种方法对组织纤维化进行无创定量的可行性，然后将这种方法应用于儿科患者。与磁共振成像相比，骨骼肌中MSOT来源的胶原蛋白含量测量与患者的功能状态高度相关，并提供了有关分子特征的其他信息。这项研究强调了MSOT成像作为一种非侵入性、与年龄无关的生物标记物的潜力，其可用于实施和监测肌肉疾病中新开发的疗法。

据介绍，对于诸如杜氏肌营养不良症之类的肌肉疾病，目前缺乏监测疾病进展和对治疗反应的生物标志物。MSOT无创体内分子成像技术使用脉冲激光诱导声压波，从而使内源性生色团可视化。

附：英文原文

Title: Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy

Author: Adrian P. Regensburger, Lina M. Fonteyne, Jrg Jngert, Alexandra L. Wagner, Teresa Gerhalter, Armin M. Nagel, Rafael Heiss, Florian Flenkenthaler, Matthias Qurashi, Markus F. Neurath, Nikolai Klymiuk, Elisabeth Kemter, Thomas Frhlich, Michael Uder, Joachim Woelfle, Wolfgang Rascher, Regina Trollmann, Eckhard Wolf, Maximilian J. Waldner, Ferdinand Knieling

Issue&Volume: 2019-12-02

Abstract: Biomarkers for monitoring of disease progression and response to therapy are lacking for muscle diseases such as Duchenne muscular dystrophy. Noninvasive in vivo molecular imaging with multispectral optoacoustic tomography (MSOT) uses pulsed laser light to induce acoustic pressure waves, enabling the visualization of endogenous chromophores. Here we describe an application of MSOT, in which illumination in the near- and extended near-infrared ranges from 680–1,100nm enables the visualization and quantification of collagen content. We first demonstrated the feasibility of this approach to noninvasive quantification of tissue fibrosis in longitudinal studies in a large-animal Duchenne muscular dystrophy model in pigs, and then applied this approach to pediatric patients. MSOT-derived collagen content measurements in skeletal muscle were highly correlated to the functional status of the patients and provided additional information on molecular features as compared to magnetic resonance imaging. This study highlights the potential of MSOT imaging as a noninvasive, age-independent biomarker for the implementation and monitoring of newly developed therapies in muscular diseases.

DOI: 10.1038/s41591-019-0669-y

Source: https://www.nature.com/articles/s41591-019-0669-y